What is Lifesci Capital’s Estimate for OKUR FY2025 Earnings?

OnKure Therapeutics (NASDAQ:OKUR) – Research analysts at Lifesci Capital issued their FY2025 earnings per share estimates for OnKure Therapeutics in a note issued to investors on Tuesday, March 11th. Lifesci Capital analyst S. Slutsky forecasts that the company will post earnings per share of ($5.14) for the year. The consensus estimate for OnKure Therapeutics’ current full-year earnings is ($4.05) per share.

OnKure Therapeutics (NASDAQ:OKUR) last announced its quarterly earnings data on Monday, March 10th. The company reported ($1.37) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.51).

Several other equities analysts have also issued reports on OKUR. Oppenheimer decreased their price target on OnKure Therapeutics from $35.00 to $30.00 and set an “outperform” rating on the stock in a research note on Tuesday. Leerink Partners began coverage on shares of OnKure Therapeutics in a research note on Thursday, December 5th. They issued an “outperform” rating and a $33.00 price objective on the stock. Finally, Leerink Partnrs upgraded shares of OnKure Therapeutics to a “strong-buy” rating in a research note on Thursday, December 5th. Three investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, OnKure Therapeutics has an average rating of “Buy” and an average target price of $34.33.

OnKure Therapeutics Price Performance

OKUR stock opened at $4.62 on Thursday. The business’s 50 day simple moving average is $5.82. The firm has a market cap of $15.44 million, a price-to-earnings ratio of -0.38 and a beta of 0.28. OnKure Therapeutics has a 1-year low of $4.55 and a 1-year high of $20.00.

Hedge Funds Weigh In On OnKure Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Acorn Capital Advisors LLC bought a new position in OnKure Therapeutics during the 4th quarter valued at approximately $12,381,000. Citadel Advisors LLC bought a new position in shares of OnKure Therapeutics during the fourth quarter valued at approximately $8,782,000. Samsara BioCapital LLC purchased a new stake in OnKure Therapeutics in the fourth quarter worth $7,088,000. Vestal Point Capital LP bought a new stake in OnKure Therapeutics in the fourth quarter valued at $5,461,000. Finally, Deep Track Capital LP purchased a new position in OnKure Therapeutics during the 4th quarter valued at $4,506,000. Institutional investors own 90.98% of the company’s stock.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.